NervGen Pharma Corporation (NGEN)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Form F-X - Appointment of Agent for Service of Process and Undertaking

Form F-10 - Registration Statement for Securities of certain Canadian Issuers.

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the...

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

NervGen Announces Proposed Public Offering of Securities

The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]